中国真菌学杂志 2022, Vol. 17 Issue (5): 408-413.
王晓娟1, 秦玉璘1, 沈春英1, 杨其莲1, 喻轶群1, 曹永兵2, 韩冰1
收稿日期:2021-03-26
发布日期:2022-10-26
通讯作者:
韩冰,E-mail:hbshcn@163.com
E-mail:hbshcn@163.com
作者简介:王晓娟,女(汉族),硕士,药师.E-mail:18221765046@163.com
基金资助:
Received:2021-03-26
Published:2022-10-26
中图分类号:
王晓娟, 秦玉璘, 沈春英, 杨其莲, 喻轶群, 曹永兵, 韩冰. 他汀类药物治疗真菌感染研究进展[J]. 中国真菌学杂志, 2022, 17(5): 408-413.
| [1] BROWN G D, DENNING D W, GOW N A, et al. Hidden killers:human fungal infections[J]. Sci Transl Med, 2012, 4(165):113r-165r. [2] NETEA M G, BROWN G D. Fungal infections:the next challenge[J]. Curr Opin Microbiol, 2012, 15(4):403-405. [3] OSTROSKY-ZEICHNER L, CASADEVALL A, GALGIANI J N, et al. An insight into the antifungal pipeline:selected new molecules and beyond[J]. Nat Rev Drug Discov, 2010, 9(9):719-727. [4] LARRU B, ZAOUTIS T E. Newer antifungal agents[J]. Curr Opin Pediatr, 2013, 25(1):110-115. [5] PFALLER M A. Antifungal drug resistance:mechanisms, epidemiology, and consequences for treatment[J]. Am J Med, 2012, 125(Suppl 1):S3-S13. [6] PRASAD R, BANERJEE A, SHAH A H. Resistance to antifungal therapies[J]. Essays Biochem, 2017, 61(1):157-166. [7] FERRI N, CORSINI A. Clinical pharmacology of statins:an update[J]. Curr Atheroscler Rep, 2020, 22(7):26. [8] ROSALES-ACOSTA B, MENDIETA A, ZÚÑIGA C, et al. Simvastatin and other inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase of Ustilago maydis (Um-Hmgr) affect the viability of the fungus, its synthesis of sterols and mating[J]. Rev Iberoam Micol, 2019, 36(1):1-8. [9] ZHOU Y, YANG H, ZHOU X, et al. Lovastatin synergizes with itraconazole against planktonic cells and biofilms of Candida albicans through the regulation on ergosterol biosynthesis pathway[J]. Appl Microbiol Biotechnol, 2018, 102(12):5255-5264. [10] ISTVAN E S, DEISENHOFER J. Structural mechanism for statin inhibition of HMG-CoA reductase[J]. Science, 2001, 292(5519):1160-1164. [11] HAMELIN B A, TURGEON J. Hydrophilicity/lipophilicity:relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors[J]. Trends Pharmacol Sci, 1998, 19(1):26-37. [12] HENNESSY E, ADAMS C, REEN F J, et al. Is there potential for repurposing statins as novel antimicrobials[J]? Antimicrob Agents Ch, 2016, 60(9):5111-5121. [13] BERGMAN P W, BJÖRKHEM-BERGMAN L. Is there a role for statins in fungal infections[J]? Expert Rev Anti-Infe, 2014, 11(12):1391-1400. [14] SCHACHTER M. Chemical, pharmacokinetic and pharmacodynamic properties of statins:an update[J]. Fundam Clin Pharmacol, 2005, 19(1):117-125. [15] NEUVONEN P J. Drug interactions with HMG-CoA reductase inhibitors (statins):the importance of CYP enzymes, transporters and pharmacogenetics[J]. Curr Opin Investig Drugs, 2010, 11(3):323-332. [16] AHMAD H, CHENG-LAI A. Pitavastatin:a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia[J]. Cardiol Rev, 2010, 18(5):264-267. [17] KITAZAWA E, TAMURA N, IWABUCHI H, et al. Biotransformation of pravastatin sodium (I) mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium[J]. Biochem Biophys Res Commun, 1993, 192(2):597-602. [18] KANTOLA T, BACKMAN J T, NIEMI M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations[J]. Eur J Clin Pharmacol, 2000, 56(3):225-229. [19] NYILASI I, KOCSUBE S, KRIZSAN K, et al. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi[J]. Fems Microbiol Lett, 2010, 307(2):175-184. [20] LIMA W G, ALVES-NASCIMENTO L A, ANDRADE J T, et al. Are the statins promising antifungal agents against invasive candidiasis[J]? Biomed Pharmacother, 2019, 111:270-281.DOI:10.1016/j.biopha.2018.12.076. [21] NATESAN S K, CHANDRASEKAR P H, ALANGADEN G J, et al. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro[J]. Diagn Microbiol Infect Dis, 2008, 60(4):369-373. [22] NYILASI I, KOCSUBE S, KRIZSAN K, et al. Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations[J]. Med Mycol, 2014, 52(2):140-148. [23] TASHIRO M, KIMURA S, TATEDA K, et al. Pravastatin inhibits farnesol production in Candida albicans and improves survival in a mouse model of systemic candidiasis[J]. Med Mycol, 2012, 50(4):353-360. [24] RIBEIRO N Q, COSTA M C, MAGALHÃES T, et al. Atorvastatin as a promising anticryptococcal agent[J]. Int J Antimicrob Agents, 2017, 49(6):695-702. [25] LEAL S J, ROY S, VAREECHON C, et al. Targeting iron acquisition blocks infection with the fungal pathogens Aspergillus fumigatus and Fusarium oxysporum[J]. Plos Pathog, 2013, 9(7):e1003436. [26] RAHAL E A, CONSTANTIN W N, ZEIDAN N, et al. Atorvastatin reduces the survival of Candida albicans-infected BALB/c mice[J]. Front Microbiol, 2015, 6:1474.DOI:10.3389/fmicb.2015.01474. [27] LIMA W G, ALVES-NASCIMENTO L A, ANDRADE J T, et al. Are the statins promising antifungal agents against invasive candidiasis[J]?Biomed Pharmacother, 2019, 111:270-281.DOI:10.1016/j.biopha.2018.12.076. [28] SPANAKIS E K, KOURKOUMPETIS T K, LIVANIS G, et al. Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery[J]. Mayo Clin Proc, 2010, 85(12):1073-1079. [29] HSU J, ANDES D R, KNASINSKI V, et al. Statins are associated with improved outcomes of bloodstream infection in solid-organ transplant recipients[J]. Eur J Clin Microbiol Infect Dis, 2009, 28(11):1343-1351. [30] CUERVO G, GARCIA-VIDAL C, NUCCI M, et al. Effect of statin use on outcomes of adults with candidemia[J]. Plos One, 2013, 8(10):e77317. [31] FORREST G N, KOPACK A M, PERENCEVICH E N. Statins in candidemia:clinical outcomes from a matched cohort study[J]. Bmc Infect Dis, 2010, 10:152.DOI:10.1186/1471-2334-10-152. [32] WELCH M L, LIAPPIS A P, KAN V L. Candidemia outcomes not improved with statin use[J]. Med Mycol, 2013, 51(2):219-222. [33] MAGULICK J P, FREI C R, ALI S K, et al. The effect of statin therapy on the incidence of infections:a retrospective cohort analysis[J]. Am J Med Sci, 2014, 347(3):211-216. [34] BHATTACHARYA S, ESQUIVEL B D, WHITE T C. Overexpression or deletion of ergosterol biosynthesis genes alters doubling time, response to stress agents, and drug susceptibility in Saccharomyces cerevisiae[J]. Mbio, 2018, 9(4):e01291-18. [35] LUPETTI A, DANESI R, CAMPA M, et al. Molecular basis of resistance to azole antifungals[J]. Trends Mol Med, 2002, 8(2):76-81. [36] GYETVAI A, EMRI T, TAKÁCS K, et al. Lovastatin possesses a fungistatic effect against Candida albicans, but does not trigger apoptosis in this opportunistic human pathogen[J]. Fems Yeast Res, 2006, 6(8):1140-1148. [37] LIU G, VELLUCCI V F, KYC S, et al. Simvastatin inhibits Candida albicans biofilm in vitro[J]. Pediatr Res, 2009, 66(6):600-604. [38] WESTERMEYER C, MACREADIE I G. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata[J]. Fems Yeast Res, 2007, 7(3):436-441. [39] BIBIKOVA M V, CHMEL' I V, SPIRIDONOVA I A, et al. Lovastatin effect on ergosterol production and growth of tolypocladium inflatum[J]. Antibiot Khimioter, 2004, 49(4):3-6. [40] MACREADIE IG, JOHNSON G, SCHLOSSER T, et al. Growth inhibition of Candida species and Aspergillus fumigatus by statins[J]. Fems Microbiol Lett, 2006, 262(1):9-13. [41] CABRAL M E, FIGUEROA L I, FARINA J I. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification[J]. Rev Iberoam Micol, 2013, 30(1):31-38. [42] ROZE L V, LINZ J E. Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus[J]. Fungal Genet Biol, 1998, 25(2):119-133. [43] BELLANGER A P, TATARA A M, SHIRAZI F, et al. Statin concentrations below the minimum inhibitory concentration attenuate the virulence of Rhizopus oryzae[J]. J Infect Dis, 2016, 214(1):114-121. [44] CALLEGARI S, MCKINNON R A, ANDREWS S, et al. Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation[J]. Fems Yeast Res, 2010, 10(2):188-198. [45] PAPPAS P G, LIONAKIS M S, ARENDRUP M C, et al. Invasive candidiasis[J]. Nat Rev Dis Primers, 2018, 4:18026.DOI:10.1038/nrdp.2018.26. [46] BRILHANTE R S, CAETANO E P, OLIVEIRA J S, et al. Simvastatin inhibits planktonic cells and biofilms of Candida and Cryptococcus species[J]. Braz J Infect Dis, 2015, 19(5):459-465. [47] JONG A, WU CH, GONZALES-GOMEZ I, et al. Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection[J]. J Biol Chem, 2012, 287(19):15298-15306. [48] JOUNEAU S, BONIZEC M, BELLEGUIC C, et al. Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis[J]. Plos One, 2011, 6(8):e22655. [49] MIRA E, LEON B, BARBER D F, et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway[J]. J Immunol, 2008, 181(5):3524-3534. [50] GALGOCZY L, NYILASI I, PAPP T, et al. Are statins applicable for the prevention and treatment of zygomycosis[J]? Clin Infect Dis, 2009, 49(3):483-485. [51] BRUCKERT E, HAYEM G, DEJAGER S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study[J]. Cardiovasc Drugs Ther, 2005, 19(6):403-414. |
| [1] | 骆明芬, 黄欢, 李倩, 刘红芳, 席丽艳. 中国大陆慢性皮肤黏膜念珠菌病回顾性分析(1980—2020年)[J]. 中国真菌学杂志, 2022, 17(5): 368-372,376. |
| [2] | 黄悦, 蔡良奇, 张子平, 程波. CHK1基因对白念珠菌体外超微结构及氟康唑最低抑菌浓度的影响[J]. 中国真菌学杂志, 2022, 17(4): 265-268,288. |
| [3] | 刘佳存, 王瑞娜, 吕权真, 阎澜. 白念珠菌耐药机制研究进展[J]. 中国真菌学杂志, 2022, 17(4): 319-323. |
| [4] | 杨成, 乔云龙, 厉荣玉, 熊延靖, 汤兴丽. 贝莱斯芽孢杆菌Y6抗菌肽抑制白念珠菌活性的研究[J]. 中国真菌学杂志, 2022, 17(3): 183-187,194. |
| [5] | 刘映禄, 冯文莉. 白念珠菌中转录因子Cap1的研究进展[J]. 中国真菌学杂志, 2022, 17(3): 231-234. |
| [6] | 张欠欠, 封小川, 张凯玄, 元航. 白念珠菌对临床常用抗真菌药物耐药机制研究进展[J]. 中国真菌学杂志, 2022, 17(3): 251-254. |
| [7] | 胡婧, 李爱红, 冯金荣. 利用大蜡螟模型研究白念珠菌SUMO编码基因SMT3在致病性调控中的作用[J]. 中国真菌学杂志, 2022, 17(2): 103-108. |
| [8] | 张露文, 冯文莉. 转录因子在白念珠菌自噬过程中的调控机制[J]. 中国真菌学杂志, 2022, 17(2): 158-162. |
| [9] | 秦玉璘, 王晓娟, 曹永兵, 吕权真, 韩冰. 外阴阴道念珠菌病的发生机制及免疫研究进展[J]. 中国真菌学杂志, 2022, 17(2): 173-176. |
| [10] | 尚元元, 李可心, 马春梅, 李莎莎, 扈容英, 杨文君. 定量PCR检测联合G试验及GM试验对侵袭性真菌感染早期诊断的价值[J]. 中国真菌学杂志, 2021, 16(6): 367-372. |
| [11] | 郭晓宇, 李小静. 白念珠菌生物膜相关基因对耐药性的影响[J]. 中国真菌学杂志, 2021, 16(6): 428-432. |
| [12] | 唐秀雅, 周万青. 西弗射盾子囊霉研究进展[J]. 中国真菌学杂志, 2021, 16(5): 351-355. |
| [13] | 张欠欠, 罗传玉, 陈嘉琪, 封小川. 白念珠菌感染现状及抗真菌药物研究进展[J]. 中国真菌学杂志, 2021, 16(5): 356-360. |
| [14] | 孟玲宁, 刘锦燕, 项明洁, 沈瀚. 白念珠菌TFP1基因与钙调神经磷酸酶通路的相关性分析[J]. 中国真菌学杂志, 2021, 16(4): 217-221. |
| [15] | 王莉, 王华, 周洁, 翟晓翔. 他克莫司与常用抗真菌药体外协同抗白念珠菌作用的初探[J]. 中国真菌学杂志, 2021, 16(4): 257-261. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
